6,431 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by MCF Advisors LLC

MCF Advisors LLC acquired a new stake in 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,431 shares of the company’s stock, valued at approximately $92,000.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC lifted its stake in 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after buying an additional 1,265 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in shares of 10x Genomics during the third quarter valued at approximately $35,000. Blue Trust Inc. lifted its position in shares of 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after acquiring an additional 1,025 shares in the last quarter. Sound Income Strategies LLC acquired a new stake in shares of 10x Genomics in the third quarter worth approximately $46,000. Finally, Venturi Wealth Management LLC increased its position in shares of 10x Genomics by 1,108.9% during the third quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock worth $55,000 after purchasing an additional 2,240 shares in the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on TXG shares. The Goldman Sachs Group lowered their target price on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a research note on Wednesday, October 30th. Canaccord Genuity Group dropped their price objective on shares of 10x Genomics from $32.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, October 10th. Barclays cut their price objective on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Citigroup lowered their target price on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. Finally, UBS Group cut their price target on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.86.

10x Genomics Trading Up 0.9 %

Shares of NASDAQ:TXG opened at $16.31 on Thursday. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of -10.66 and a beta of 1.83. 10x Genomics, Inc. has a 12-month low of $12.95 and a 12-month high of $51.22. The business has a 50-day moving average price of $14.98 and a 200 day moving average price of $17.89.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The business had revenue of $151.65 million during the quarter, compared to analysts’ expectations of $158.84 million. During the same period last year, the business earned ($0.51) earnings per share. The business’s revenue for the quarter was down 1.3% on a year-over-year basis. As a group, equities research analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.